THE loss of dark adaptation and night blindness which characterizes the earliest stages of retinitis pigmentosa suggested to us the possibility that one of the fundamental features of the ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds, described in a study published January 14 in the open-access ...

aSection of Musculoskeletal Disease, NIHR Leeds Musculoskeletal Biomedical Research Centre, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, ...

Retinitis pigmentosa is a relatively rare genetic disorder (affecting 1 in 3,500 people), while age-related macular degeneration affects 7–8% of the population, and its incidence increases with age.

VP-001 is under clinical development by PYC Therapeutics and currently in Phase I for Retinitis Pigmentosa (Retinitis). According to GlobalData, Phase I drugs for Retinitis Pigmentosa (Retinitis) have ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds, described in a study published January 14 th in the open-access ...

Scientists have identified two non-retinoid compounds that may be able to treat retinitis pigmentosa (RP), a group of inherited eye diseases that cause blindness. The compounds were discovered by ...